Sunitinib rechallenge in advanced renal cell carcinoma: outcomes of a multicenter retrospective study.
Javier Munárriz, Gaspar Reynés, Luisa Sánchez-Lorenzo, Emilio Esteban, Laura Basterretxea, Leticia de Avila-Lizárraga, Miguel Angel Climent, María José Juan-Fita, Corina Escoín, Javier Puente, Javier Cassinello, Sergio Vázquez, Isabel Chirivella
Author Information
Javier Munárriz: Department of Medical Oncology, Consorci Hospitalari Provincial de Castelló, Castelló, Spain.
Gaspar Reynés: Instituto de Investigación Sanitaria La Fe, Valencia, Spain. greynesm@gmail.com. ORCID
Luisa Sánchez-Lorenzo: Clínica Universidad de Navarra, Campus Madrid, Madrid, Spain.
Emilio Esteban: Hospital Universitario Central de Asturias, Oviedo, Spain.
Leticia de Avila-Lizárraga: Hospital San Pedro, Logroño, Spain.
Miguel Angel Climent: Instituto Valenciano de Oncología, Valencia, Spain.
María José Juan-Fita: Instituto Valenciano de Oncología, Valencia, Spain.
Corina Escoín: Hospital Universitario de La Ribera, Valencia, Spain.
Javier Puente: Medical Oncology Department, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), CIBERONC, Madrid, Spain.
Javier Cassinello: Hospital Universitario de Guadalajara, Guadalajara, Spain.
PURPOSE: The aim of this multicenter study was to evaluate the clinical outcomes of patients with metastatic renal cell carcinoma (mRCC) who received sunitinib retreatment. METHODS: Clinical data from patients treated with sunitinib rechallenge in nine Spanish centers were retrospectively analyzed. All patients received first-line sunitinib until progression or intolerance, followed by one or more successive drugs and rechallenge with sunitinib thereafter. RESULTS: Thirty-seven patients were included. At first-line treatment, objective response rate (ORR) was 69.4% and median progression-free survival (PFS) was 19.4 months. At rechallenge, ORR was 27.2% and 39.4% of patients obtained stabilization of disease. Median PFS was 6.2 months. Clinical benefit was obtained by 21 patients (75%) with > 6-month interval between sunitinib treatments and by 1 patient (20%) among those with ≤ 6-month interval (P = 0.016). Hemoglobin levels ≥ lower level of normal were associated with clinical benefit (P = 0.019) and with PFS (P = 0.004). Median overall survival from start of first-line sunitinib was 52.7 months. No new adverse events were observed at rechallenge. CONCLUSIONS: Sunitinib rechallenge is a feasible treatment option for selected patients with mRCC.
